CL2016002918A1 - Compuestos derivados de quinazolina-4(3h)-ona-n-hidroxi-2-metil-2-metilsulfonil-butanamida; composicion farmaceutica; actividad antibacteriana gram-negativo. - Google Patents

Compuestos derivados de quinazolina-4(3h)-ona-n-hidroxi-2-metil-2-metilsulfonil-butanamida; composicion farmaceutica; actividad antibacteriana gram-negativo.

Info

Publication number
CL2016002918A1
CL2016002918A1 CL2016002918A CL2016002918A CL2016002918A1 CL 2016002918 A1 CL2016002918 A1 CL 2016002918A1 CL 2016002918 A CL2016002918 A CL 2016002918A CL 2016002918 A CL2016002918 A CL 2016002918A CL 2016002918 A1 CL2016002918 A1 CL 2016002918A1
Authority
CL
Chile
Prior art keywords
quinazoline
methylsulfonyl
hydroxy
methyl
butanamide
Prior art date
Application number
CL2016002918A
Other languages
English (en)
Inventor
Azely Mirre
Jean-Phillippe Surivet
Gaëlle Chapoux
Jean-Christophe Gauvin
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CL2016002918A1 publication Critical patent/CL2016002918A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/90Oxygen atoms with acyclic radicals attached in position 2 or 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos derivados de compuestos derivados quinazolina-4(3H)-ona-N-hidroxi-2-metil-2-metilsulfonil-butanamida con actividad antibacteriana Gram negativo
CL2016002918A 2014-05-16 2016-11-16 Compuestos derivados de quinazolina-4(3h)-ona-n-hidroxi-2-metil-2-metilsulfonil-butanamida; composicion farmaceutica; actividad antibacteriana gram-negativo. CL2016002918A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14168718 2014-05-16

Publications (1)

Publication Number Publication Date
CL2016002918A1 true CL2016002918A1 (es) 2017-04-07

Family

ID=50731968

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002918A CL2016002918A1 (es) 2014-05-16 2016-11-16 Compuestos derivados de quinazolina-4(3h)-ona-n-hidroxi-2-metil-2-metilsulfonil-butanamida; composicion farmaceutica; actividad antibacteriana gram-negativo.

Country Status (19)

Country Link
US (1) US9796686B2 (es)
EP (1) EP3143007B1 (es)
JP (1) JP2017515906A (es)
KR (1) KR20170005105A (es)
CN (1) CN106458931A (es)
AR (1) AR100428A1 (es)
AU (1) AU2015261540A1 (es)
BR (1) BR112016026787A8 (es)
CA (1) CA2948077A1 (es)
CL (1) CL2016002918A1 (es)
EA (1) EA201692305A1 (es)
ES (1) ES2687040T3 (es)
IL (1) IL248922A0 (es)
MX (1) MX2016014989A (es)
PH (1) PH12016502253A1 (es)
SG (1) SG11201609286VA (es)
TW (1) TW201625559A (es)
WO (1) WO2015173329A1 (es)
ZA (1) ZA201608680B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
EA030730B1 (ru) 2013-12-19 2018-09-28 Идорсиа Фармасьютиклз Лтд Антибактериальные производные 1h-индазола и 1h-индола
AR099612A1 (es) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
AR105646A1 (es) * 2015-08-11 2017-10-25 Actelion Pharmaceuticals Ltd Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
CA2991281A1 (en) * 2015-08-28 2017-03-09 Idorsia Pharmaceuticals Ltd Antibacterial annulated pyrrolidin-2-one derivatives
AR105889A1 (es) 2015-09-03 2017-11-22 Actelion Pharmaceuticals Ltd Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
EP3386950A1 (en) 2015-12-08 2018-10-17 GlaxoSmithKline Intellectual Property Development Limited Substituted benzazinones as antibacterial compounds
KR20220071293A (ko) 2016-04-01 2022-05-31 리커리엄 아이피 홀딩스, 엘엘씨 에스트로겐 수용체 조절제
JP6812542B2 (ja) * 2016-09-28 2021-01-13 ドン−ア エスティ カンパニー リミテッド テトラヒドロピリジン誘導体および抗菌剤としてのその使用
KR20220044528A (ko) 2019-08-06 2022-04-08 리커리엄 아이피 홀딩스, 엘엘씨 돌연변이체를 치료하기 위한 에스트로겐 수용체 조절제

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU40999A (sh) 1997-02-27 2002-06-19 American Cyanamid Company N-hidroksi-2-(alkil,aril ili heteroaril sulfanil,sulfinil ili sulfonil)-3-supstituisani alkil,aril ili heteroarilamidi, kao inhibitori za matrične metaloproteinaze
KR100984595B1 (ko) 2002-03-13 2010-09-30 어레이 바이오파마 인크. Mek 억제제로서의 n3 알킬화 벤즈이미다졸 유도체
TWI519508B (zh) * 2007-06-12 2016-02-01 Achaogen Inc 抗菌劑
JP5455913B2 (ja) 2008-08-27 2014-03-26 大正製薬株式会社 ナフチリジン−n−オキシドを有する新規ヒドロキサム酸誘導体
EP2350039A4 (en) 2008-10-03 2012-10-10 Boehringer Ingelheim Int INHIBITORS OF VIRAL POLYMERASE
DE102008044132A1 (de) 2008-11-27 2010-06-02 BSH Bosch und Siemens Hausgeräte GmbH Kältegerät mit zweiseitig anschlagbarer Tür
EP2432468A2 (en) 2009-05-20 2012-03-28 Ardea Biosciences, Inc. Methods of modulating uric acid levels
WO2011045703A2 (en) 2009-10-13 2011-04-21 Pfizer Inc. C-linked hydroxamic acid derivatives useful as antibacterial agents
WO2011073845A1 (en) 2009-12-16 2011-06-23 Pfizer Inc. N-linked hydroxamic acid derivatives useful as antibacterial agents
US8765773B2 (en) 2010-10-18 2014-07-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
MX2013005200A (es) 2010-11-10 2013-06-28 Achaogen Inc Derivados de acido hidroxamico y su so en el tratamiento de infecciones bacterianas.
CN103328482A (zh) 2011-01-03 2013-09-25 韩美药品株式会社 用于调节g蛋白-偶联受体的新双环化合物
ES2626457T3 (es) * 2011-03-07 2017-07-25 Pfizer Inc. Derivados de fluoro-piridinona útiles como agentes antibacterianos
CA2830866A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
ES2526687T3 (es) 2011-04-08 2015-01-14 Pfizer Inc. Derivados de isoxazol útiles como agentes antibacterianos
US9260452B2 (en) 2011-06-08 2016-02-16 Sunovion Pharmaceuticals Inc. Metabotrophic glutamate receptor 5 modulators and methods of use thereof
EP2847162A1 (en) 2012-05-09 2015-03-18 Achaogen, Inc. Antibacterial agents
EP2847168A1 (en) * 2012-05-10 2015-03-18 Achaogen, Inc. Antibacterial agents
US10647664B2 (en) 2013-08-16 2020-05-12 Duke University Substituted hydroxamic acid compounds
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
EA030730B1 (ru) 2013-12-19 2018-09-28 Идорсиа Фармасьютиклз Лтд Антибактериальные производные 1h-индазола и 1h-индола
AR099612A1 (es) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona

Also Published As

Publication number Publication date
ZA201608680B (en) 2018-11-28
EP3143007A1 (en) 2017-03-22
IL248922A0 (en) 2017-01-31
US20170081292A1 (en) 2017-03-23
EA201692305A1 (ru) 2017-05-31
BR112016026787A2 (es) 2017-08-15
AR100428A1 (es) 2016-10-05
US9796686B2 (en) 2017-10-24
BR112016026787A8 (pt) 2017-12-26
CN106458931A (zh) 2017-02-22
AU2015261540A1 (en) 2017-01-12
EP3143007B1 (en) 2018-07-11
CA2948077A1 (en) 2015-11-19
JP2017515906A (ja) 2017-06-15
KR20170005105A (ko) 2017-01-11
ES2687040T3 (es) 2018-10-23
MX2016014989A (es) 2017-03-31
SG11201609286VA (en) 2016-12-29
WO2015173329A1 (en) 2015-11-19
PH12016502253A1 (en) 2017-01-16
TW201625559A (zh) 2016-07-16

Similar Documents

Publication Publication Date Title
CL2016002918A1 (es) Compuestos derivados de quinazolina-4(3h)-ona-n-hidroxi-2-metil-2-metilsulfonil-butanamida; composicion farmaceutica; actividad antibacteriana gram-negativo.
EP3621962A4 (en) ANTIBACTERIAL COMPOUNDS
SI3256138T1 (sl) Farmacevtski sestavki, ki obsegajo meloksikam
GEP20217239B (en) Pharmaceutical composition
EP3036639A4 (en) STORAGE CLUSTER
BR112016023628A2 (pt) composições farmacêuticas.
EP3497210A4 (en) INNOVATIVE GLUCOSE OXIDASE COMPOSITIONS
EP3621961A4 (en) Antibacterial compounds
EP3102193A4 (en) Antibacterial agents: n(alpha)-aroyl-n-aryl-phenylalaninamides
EP3236978C0 (en) An antimicrobial composition
BR112016021012A2 (pt) composições farmacêuticas de compostos terapeuticamente ativos.
EP3126376C0 (en) POLYMYXIN DERIVATIVES USED AS ANTIMICROBIAL COMPOUNDS
FR3024465B1 (fr) Caracterisation de micro-organismes par maldi-tof
FI20165137A7 (fi) Ekspressiojärjestelmä eukaryoottisille mikro-organismeille
CL2016001349A1 (es) Uso de derivados de bencimidazol-prolina
GEP20217240B (en) Pharmaceutical composition
CL2015000430S1 (es) Alumbrado exterior.
BR112017013156A2 (pt) combinações de composto ativo.
LT3119198T (lt) Semiocheminės kompozicijos, skirtos sumažinti socialinį konfliktą tarp kačių
MX386975B (es) Fármacos precursores de oxabicicloheptanos.
ECSP17014972A (es) Compuestos de azetidiniloxifenilpirrolidina
BR112017013013A2 (pt) combinações de composto ativo
BR112017012801A2 (pt) combinações de composto ativo.
FR3020948B1 (fr) Composition antimicrobienne
EP3436923A4 (en) STORAGE CLUSTER